

State of Oklahoma



SoonerCare Cotellic[®] (Cobimetinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:	
	Drug Info	rmation	
Phar	macy billing (NDC:)	
Dose:	Regimen:	Start Date:	
	Billing Provide	r Information	
Provider NPI:	Provid	er Name:	
Provider Phone:	vider Phone: Provider Fax:		
	Prescriber I	nformation	
Prescriber NPI: Prescriber Name:		Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:	
	Crite	ria	
 A. Does memby Yes No B. Is melanoma C. Will cobimeted D. Will cobimeted Yes No C. Histiocytic Neo A. Will cobimeted 	r Metastatic Melanoma er have BRAF V600E or V600 a wild-type BRAF? Yes N inib be used as first-line therap inib be used as second-line the plasm inib be used as a single agent	by in combination with vemurafenib? Yes No erapy or subsequent therapy with vemurafenib?	
 Has the member experience If yes, please specify adverse Additional Information: Prescriber Signature: I certify that the indicated tree 	evidence of progressive diseas enced any adverse drug reactions: se reactions: eatment is medically necessary		
Fax completed prior au 888-601-8461 or submit Elec CoverMyMeds® or S data must be provided. Inc the chart notes will be re Guidelines	uthorization request form to tronic Prior Authorization through sureScripts. All requested omplete forms or forms without turned. Pharmacy Coverage are available at ath.com/Oklahoma.	CONFIDENTIALITY NOTICE This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the retur of the transmitted documents or to verify their destruction.	